CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Caris Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$30.71+0.15 (+0.49%)
Close on Oct 19, 2026
- Market cap
- $8.69B
- P/E (TTM)
- –
- Dividend yield
- –
Caris Life Sciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Cost of services - Molecular profiling services | $766.72M | $349.12M | $278.75M | 94.4% | +119.6% |
| Cost of services - Pharma research and development services | $45.31M | $63.15M | $27.38M | 5.6% | -28.2% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $801.39M | $401.84M | $293.41M | 98.7% | +99.4% |
| International | $10.64M | $10.42M | $12.72M | 1.3% | +2.1% |
From the segment and revenue-disaggregation notes of Caris Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.